ClinicalTrials.gg
TerminatedNCT02615938HCQ-chILD-EUUpdated Dec 3, 2025Results posted

Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)

A Phase 2 interventional study of Hydroxychloroquine sulfate and Placebo in Interstitial Lung Disease, Diffuse Parenchymal Lung Disease and Children´s Interstitial Lung Disease, sponsored by Matthias Griese. Terminated at 9 sites in Germany. Open to participants aged 3 Weeks to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Matthias Griese · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Lack of ressources after inspection and appropriate correcting actions to be taken

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
3 Weeks to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Lung Diseases, Interstitial with a site in Germany — 18 open to participants now, 26 under way, 13 of them phase 3. Lung Diseases, Interstitial · Germany.

Enrollment
43rd of 51
35 · median 183
Started
2015
with 3 others
Phase 2
15 of 66
3 open now
Registered
17th of 66
by date
Lead sponsor
2 of 66
Matthias Griese

Among the 66 studies in Lung Diseases, Interstitial with a site in Germany, this one is the 43rd largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2015, is one of 15 in phase 2, and was the 17th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

18 of the 66 studies in Lung Diseases, Interstitial with a site in Germany are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 3 Weeks to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Lung Diseases, Interstitial with a site in Germany, or all of them as a file.
02

Study summary

This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.

Read the detailed description

This study is an explorative, prospective, randomized, double-blind, placebo controlled investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each patient can participate in each block only once. In the START block subjects are randomized to parallel-groups, then the placebo group is switched to active drug. In the STOP block, subjects on HCQ are randomized into parallel-groups treated with placebo or HCQ to investigate the withdrawal of HCQ for assessment of its efficacy.

03

Conditions studied

  • Interstitial Lung Disease
  • Diffuse Parenchymal Lung Disease
  • Children´s Interstitial Lung Disease

Keywords

  • Childhood ILD
  • Fibrosing lung disease
04

Who can participate

Ages eligible
3 Weeks to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients should be clinically stable during baseline (between Visit 1 and 2) for inclusion into the study

    1. To determine this, attending physicians can use SpO2 in room air for patients on room air or on O2-supplement; the absolute difference on SpO2 is expected not to be ≥ 5% between Visit 1 and 2. For patients on respiratory support, the summary key parameters should not change ≥ 20% between Visit 1 and 2 and
    2. No major changes in other medications between Visit 1 and 2
  2. Mature newborn ≥ 37 weeks of gestation, age ≥ 3 wks and \<2y or Infants and children (≥2y and \< 18y) or Adults (≥18 and ≤30y) or Previously preterm (≤ 37 weeks of gestation) babies or children and adults of all ages if chILD genetically diagnosed (see inclusion criterion 3.)
  3. Diagnosis of chronic (≥ 3 wks of duration) diffuse parenchymal lung disease (DPLD = chILD), defined in at least one of the following ways:

    1. chILD genetically diagnosed surfactant dysfunction disorders including patients with mutations in SFTPC, SFTPB, ABCA3, TTF1 (Nkx2-1), further extremely rare entities with specific mutations, for example in TBX4, NPC2, NPC1, NPB, COPA, LRBA and other genes. In this case, also previously preterm (≤ 37 weeks of gestation) babies or children and adults of all ages can be included into the study.
    2. chILD diagnosed

      • Chronic pneumonitis of infancy (CPI)
      • Desquamative interstitial pneumonia (DIP)
      • Lipoid pneumonitis / Cholesterol pneumonia
      • Nonspecific interstitial pneumonia (NSIP)
      • PAP after the exclusion of mutations in GMCSF-Ra/b and GMCSF autoantibodies*
      • Usual interstitial pneumonia (UIP)
      • Follicular bronchitis/bronchiolitis/Lymphocytic interstitial pneumonia (LIP)
      • Storage disease with primary pulmonary involvement (e.g. Niemann Pick)
      • Hermansky-Pudlak Syndrome
      • Idiopathic pulmonary haemorrhage (haemosiderosis)*
      • Other histology diagnosing chILD, in particular combination of the above pattern, but not exclusively
  4. Start block: no HCQ treatment in the last 12 weeks Stop block: stable HCQ treatment for at least the last 12 weeks
  5. Ability of subject or/and legal representatives to understand character and individual consequences of clinical trial.
  6. Signed and dated of the subject (if subject has the ability) and the representatives (of underaged children) must be available before start of any specific trial procedures.

(*may be diagnosed in the absence of a lung by characteristic lung lavage cytology (PAS stain, Fe stain), CT pattern or autoantibodies (gliadin, endomysium; cANCA) and clinical course.)

Exclusion criteria

Exclusion criteria:

Subjects presenting with any of the following criteria will not be included in the trial:

  • chILD primarily related to developmental disorders
  • chILD primarily related to growth abnormalities reflecting deficient alveolarisation
  • chILD related to chronic aspiration
  • chILD related to immunodeficiency
  • chILD related to abnormalities in lung vessel structure
  • chILD related to organ transplantation/organ rejection/GvHD
  • chILD related to recurrent infections
  • Acute severe infectious exacerbations
  • Known to HCQ, or other ingredients of the tablets (lactose-monohydrate, povidone, maize starch, magnesium stearate, hypromellose, macrogol or titanium dioxide (E 171), silicon dioxide or mannitol), to sucrose-octaacetate or sodium saccharine.
  • Proven retinopathy or maculopathy
  • Glucose-6-phosphate-dehydrogenase deficiency resulting in favism or hemolytic anemia
  • Myasthenia gravis
  • Hematopoetic disorders
  • Pregnancy and lactation (Women with have to practice a medically accepted during trial and till three months after the end of the treatment with HCQ, and a negative pregnancy test (serum or urine) should be existent on Visit 1, if girls of childbearing age and only if sexual relations are known or probable. It is at the discretion and responsibility of the attending physician to decide, whether a pregnancy test is necessary or not. Reliable contraception are systematic contraceptives (oral, implant, injection). Women that are sterile by surgery can participate in the trial. At the discretion of the investigator, sexual abstinence is also accepted as contraceptive method. Girls after menarche have to receive a counselling about birth control methods in presence of at least one parent, which has to be documented in the patient notes.
  • Participation in other clinical trials during the present clinical trial or not beyond the time of 4 half-lives of the medication used, at least one week.
  • Hereditary galactose intolerance, lactase deficiency or glucose-galactose- malabsorption
  • Renal insufficiency at screening, defined as (GFR)

    • \< 40 mL/min/1.73 m2 in patients age 3 to 8 weeks
    • \< 60 mL/min/1.73 m2 in patients ≥ 8 weeks of age (KDIGO guideline 2012, K/DOQI guideline 2002)
  • Liver disease, gastrointestinal disorder, haematological disorder, epilepsy or other neurological disorder, psoriasis, porphyria at the discretion of the treating physician
  • Simultaneous prescription of other potentially nephrotoxic or hepatotoxic medication at the discretion of the treating physician
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Start HCQ block Verum

    4 weeks of Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., once daily dose in the evening for 7 days, then reduction to 6.5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400 mg. Then 4 weeks Hydroxychloroquine Sulfate (HCQ, Quensyl). First week loading dose 10 mg/kg bw/d, p.o., once daily in the evening, followed by 6.5 mg/kg bw/d for 3 weeks.

    Drug: Hydroxychloroquine sulfate

  • Placebo comparator
    Start HCQ block Placebo

    4 weeks of Placebo in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6.5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400 mg. Then 4 weeks Hydroxychloroquine Sulfate (HCQ, Quensyl). First week loading dose 10 mg/kg bw/d, p.o., once daily in the evening, followed by 6.5 mg/kg bw/d for 3 weeks.

    Other: Placebo

  • Experimental
    Stop HCQ block Verum

    Individual dose of Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., once daily in the evening; the maximum daily dose is 400 mg. The dose on which the patient was included into the trial was continued for 3 months. Then the medication was stopped and the patient followed for additional 3 months.

    Drug: Hydroxychloroquine sulfate

  • Placebo comparator
    Stop HCQ block Placebo

    Individual dose of Placebo 6-10 mg/kg bw/d, p.o., once daily in the evening; the maximum daily dose is 400 mg. The dose on which the patient was included into the trial was continued for 3 months. Then the medication was stopped and the patient wo received HCQ will be followed up for additional 3 months with no medication.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=5%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary

    O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=5%, or change in respiratory rate \>=20%, or change in respiratory support necessary

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

Secondary outcomes

  1. Change in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=3%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary

    O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=3%, or change in respiratory rate \>=20%, or change in respiratory support necessary

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  2. Change of O2-sat in Room Air (%)

    Oxygen saturation in room air at rest

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  3. Change of Respiratory Rate in Room Air (Breaths/Min)

    Respiratory rate in room air at rest measured in breaths per minute

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  4. Change of Quality of Life (chILD Specific)

    Quality of life (chILD specific) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  5. Change of Quality of Life (Total Score)

    Quality of life (total score) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  6. Change of BMI Percentile

    BMI percentile to adapt for age and sex related differences

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  7. Change of LDH (U/ml)

    Lactate dehydrogenase

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  8. Absolute Change of Forced Vital Capacity (FVC) (% Predicted of the Reference Population)

    FVC predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.) The absolute change in FVC % predicited between two measurements is reported.

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  9. Absolute Change of Forced Expiratory Volume in One Second (FEV1) (% Predicted of the Reference Population)

    FEV1 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in FEV1 % predicited between two measurements is reported.

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  10. Absolute Change of Mean Expiratory Flow Between 25 and 75% of Vital Capacity (MEF25-75) (% Predicted of the Reference Population)

    MEF25-75 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in MEF25-75 % predicited between two measurements is reported.

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

  11. Absolute Change of Six Minute Walking Test (6MWT) Distance (% Predicted of the Reference Population)

    6 Minute walking distance expressed as % of the predicted distance for age and sex. Ulrich et al, Reference values for the 6-minute walk test. BMC Pulm Med. 2013 Aug 5:13:49. doi: 10.1186/1471-2466-13-49. The absolute difference of two measuremnts between two time points is reported.

    Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks

07

Results

Posted Dec 3, 2025
Limitations and caveats
Limitations include not reaching the target number of participants. As this was the first randomized controlled trial in fibrosing chILD performed ever, the study was exploratory and there was no formal sample size calculation. Including more patients was prevented by interference with an authority inspection, COVID19 pandemic and the ultra-rare conditions targeted. See for more details Orphanet J Rare Dis. 2022 Jul 23;17(1):289. doi: 10.1186/s13023-022-02399-2. PMID: 35871071.

Participant flow

First 4 Wks Start, First 3 Mon Stop
Participant flow — First 4 Wks Start, First 3 Mon Stop
MilestoneStart Placebo, Then HCQStart HCQ, Then HCQStop HCQ, Then no MedicationStop Placebo, Then no Medication
Started17945
Completed13735
Not completed4210
Withdrew: Physician decision3200
Withdrew: Withdrawal by subject1000
Withdrew: Physician decision0010
Second 4 Wks Start, 2nd 3 Mon Stop
Participant flow — Second 4 Wks Start, 2nd 3 Mon Stop
MilestoneStart Placebo, Then HCQStart HCQ, Then HCQStop HCQ, Then no MedicationStop Placebo, Then no Medication
Started13735
Completed12735
Not completed1000

Outcome measures

PrimaryChange in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=5%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary

O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=5%, or change in respiratory rate \>=20%, or change in respiratory support necessary

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Count of participants · Participants
Change in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=5%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary
ParticipantsStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Responder00300011
Non-responder137973524
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · Fisher Exact · p = 1No estimated value can be calculated if in any group no responder exists (i.e. no odds exists for independent groups)
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) ·
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · Fisher Exact · p = 1.0No estimated value can be calculated if in any group no responder exists (i.e. no odds exists for independent groups)
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) ·
SecondaryChange in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=3%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary

O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=3%, or change in respiratory rate \>=20%, or change in respiratory support necessary

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Count of participants · Participants
Change in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=3%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary
ParticipantsStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Responder21200311
Non-responder1151063224
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · Fisher Exact · p = 1.0 · Odds ratio (or): 1 · 1.1% CI 0.079 to 15.16
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · McNemar · p = 1.0 · Odds ratio (or): -0.2 · 95% CI -0.340 to 0.008
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · Fisher Exact · p = 0.196No estimated value can be calculated if in any group no responder exists (i.e. no odds exists for independent groups)
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) ·
SecondaryChange of O2-sat in Room Air (%)

Oxygen saturation in room air at rest

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · percentage of O2 Sat
Change of O2-sat in Room Air (%)
percentage of O2 SatStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Change of O2-sat in Room Air (%)-0.1 ± 2.4-0.6 ± 3.31.8 ± 3.5-1.7 ± 2.60.3 ± 1.2-2.4 ± 2.7-3.7 ± 6.40.2 ± 4.8
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.757 · Mean difference (net): -0.2 · 95% CI -1.2 to 0.8
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.229 · Mean difference (net): 0.6 · 95% CI -0.2 to 1.1
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.097 · Mean difference (net): -1.2 · 95% CI -2.7 to 0.4
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.427 · Mean difference (net): -0.9 · 95% CI -2.5 to 0.8
SecondaryChange of Respiratory Rate in Room Air (Breaths/Min)

Respiratory rate in room air at rest measured in breaths per minute

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · breaths/min
Change of Respiratory Rate in Room Air (Breaths/Min)
breaths/minStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Change of Respiratory Rate in Room Air (Breaths/Min)1.2 ± 5.40.2 ± 0.4-1.3 ± 5.613.8 ± 33.1-2.7 ± 1.2-5.4 ± 9.47.3 ± 52.5 ± 7.9
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.543 · Mean difference (net): -0.2 · 95% CI -1.2 to 0.8
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.421 · Mean difference (net): -0.5 · 95% CI -1.2 to 0.3
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.553 · Mean difference (net): -0.4 · 95% CI -1.8 to 1.1
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group H) · t-test, 2 sided · p = 0.1020 · Mean difference (net): -2.8 · 95% CI -5 to -0.5
SecondaryChange of Quality of Life (chILD Specific)

Quality of life (chILD specific) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · score on a scale
Change of Quality of Life (chILD Specific)
score on a scaleStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Change of Quality of Life (chILD Specific)6.9 ± 9.60.1 ± 3.18-3.2 ± 4.8-9.1 ± 3.25-5.7 ± 11.27.5 ± 2.32.3 ± 3.2-2.0 ± 12.3
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.178 · Mean difference (net): -0.8 · 95% CI -2.4 to 0.9
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.110 · Mean difference (net): -1.3 · 95% CI -2.6 to -0.1
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.338 · Mean difference (net): 1.6 · 95% CI -0.6 to 3.9
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) vs Stop Placebo, Then no Medication (Group H) · t-test, 2 sided · p = 0.3979 · Mean difference (net): -1.0 · 95% CI -3 to 1.1
SecondaryChange of Quality of Life (Total Score)

Quality of life (total score) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · score on a scale
Change of Quality of Life (Total Score)
score on a scaleStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Change of Quality of Life (Total Score)0.4 ± 6.90.3 ± 1.24.8 ± 4.30.4 ± 7.09.2 ± 5.4-9.5 ± 8.8-1.7 ± 2.3-5.5 ± 4.3
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.965 · Mean difference (net): 0 · 95% CI -1.6 to 1.6
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.374 · Mean difference (net): 0.8 · 95% CI -0.4 to 1.9
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.149 · Mean difference (net): -2.6 · 95% CI -5.2 to 0.1
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.2963 · Mean difference (net): 2.6 · 95% CI 0 to 5.3
SecondaryChange of BMI Percentile

BMI percentile to adapt for age and sex related differences

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · percentile
Change of BMI Percentile
percentileStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Change of BMI Percentile7.5 ± 11.7-1.8 ± 5.1-1.6 ± 8.122.6 ± 43.7-3.3 ± 7.92.2 ± 11.413.3 ± 20.93.9 ± 9.2
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.024 · Mean difference (net): -0.9 · 95% CI -1.9 to 0
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.045 · Mean difference (net): -0.9 · 95% CI -1.7 to -0.1
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.458 · Mean difference (net): 0.5 · 95% CI -0.9 to 2.0
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.4216 · Mean difference (net): -1.1 · 95% CI -2.8 to 0.7
SecondaryChange of LDH (U/ml)

Lactate dehydrogenase

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · Enzyme activity units per ml
Change of LDH (U/ml)
Enzyme activity units per mlStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Change of LDH (U/ml)-28.2 ± 53.743.0 ± 6111.3 ± 67-32.2 ± 55.334.5 ± 0.79.3 ± 65.5——
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.063 · Mean difference (net): 1.3 · 95% CI 0.1 to 2.5
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.410 · Mean difference (net): 0.6 · 95% CI -0.3 to 1.6
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.574 · Mean difference (net): -0.5 · 95% CI -2.3 to 1.3
SecondaryAbsolute Change of Forced Vital Capacity (FVC) (% Predicted of the Reference Population)

FVC predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.) The absolute change in FVC % predicited between two measurements is reported.

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · percentage of reference population
Absolute Change of Forced Vital Capacity (FVC) (% Predicted of the Reference Population)
percentage of reference populationStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Absolute Change of Forced Vital Capacity (FVC) (% Predicted of the Reference Population)0.0 ± 3.72.5 ± 1310.6 ± 19.7-1.0 ± 4.22.3 ± 7.60.5 ± 2.1-1.3 ± 5.14.5 ± 4.9
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.730 · Mean difference (net): 0.3 · 95% CI -0.9 to 1.5
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.170 · Mean difference (net): 0.7 · 95% CI -0.3 to 1.8
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.724 · Mean difference (net): -0.3 · 95% CI -2.1 to 1.5
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.487 · Mean difference (net): -0.6 · 95% CI -2.2 to 1.1
SecondaryAbsolute Change of Forced Expiratory Volume in One Second (FEV1) (% Predicted of the Reference Population)

FEV1 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in FEV1 % predicited between two measurements is reported.

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · percentage of reference population
Absolute Change of Forced Expiratory Volume in One Second (FEV1) (% Predicted of the Reference Population)
percentage of reference populationStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Absolute Change of Forced Expiratory Volume in One Second (FEV1) (% Predicted of the Reference Population)0.6 ± 4.12.0 ± 13.19.0 ± 18.60.5 ± 5.10.0 ± 4.4-0.5 ± 0.7-1.0 ± 4.45.5 ± 4.9
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.850 · Mean difference (net): 0.2 · 95% CI -1 to 1.4
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.258 · Mean difference (net): 0.6 · 95% CI -0.4 to 1.6
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.862 · Mean difference (net): -0.1 · 95% CI -1.9 to 1.7
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.840 · Mean difference (net): -0.2 · 95% CI -1.8 to 1.4
SecondaryAbsolute Change of Mean Expiratory Flow Between 25 and 75% of Vital Capacity (MEF25-75) (% Predicted of the Reference Population)

MEF25-75 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in MEF25-75 % predicited between two measurements is reported.

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · percentage of reference population
Absolute Change of Mean Expiratory Flow Between 25 and 75% of Vital Capacity (MEF25-75) (% Predicted of the Reference Population)
percentage of reference populationStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Absolute Change of Mean Expiratory Flow Between 25 and 75% of Vital Capacity (MEF25-75) (% Predicted of the Reference Population)3.0 ± 13.1-14.8 ± 15.2-2.6 ± 8.618.5 ± 17.4-8.7 ± 14.2-7.0 ± 1.4-11.3 ± 7.815.5 ± 6.4
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · t-test, 2 sided · p = 0.010 · Mean difference (net): -1.3 · 95% CI -2.6 to 0
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.533 · Mean difference (net): -0.5 · 95% CI -1.5 to 0.5
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.858 · Mean difference (net): 0.1 · 95% CI -1.6 to 1.9
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.661 · Mean difference (net): 0.2 · 95% CI -1.4 to 1.8
SecondaryAbsolute Change of Six Minute Walking Test (6MWT) Distance (% Predicted of the Reference Population)

6 Minute walking distance expressed as % of the predicted distance for age and sex. Ulrich et al, Reference values for the 6-minute walk test. BMC Pulm Med. 2013 Aug 5:13:49. doi: 10.1186/1471-2466-13-49. The absolute difference of two measuremnts between two time points is reported.

Time frame:
Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Reported as:
Mean · percentage of reference population
Absolute Change of Six Minute Walking Test (6MWT) Distance (% Predicted of the Reference Population)
percentage of reference populationStart Placebo, Then HCQ (Group A)Start HCQ, Then HCQ (Group B)Start Placebo, Then HCQ (Group C)Start HCQ, Then HCQ (Group D)Stop HCQ, Then no Medication (Group E)Stop Placebo, Then no Medication (Group F)Stop HCQ, Then no Medication (Group G)Stop Placebo, Then no Medication (Group H)
Absolute Change of Six Minute Walking Test (6MWT) Distance (% Predicted of the Reference Population)-0.8 ± 3.6-31.0 ± NA0.8 ± 2.144 ± NA0.3 ± 8.5-0.5 ± 2.18.7 ± 12.6-3.0 ± 2.8
Statistical analysis
  • Start Placebo, Then HCQ (Group A) vs Start HCQ, Then HCQ (Group B) · Mean difference (net): -8.4 · 95% CI -14 to -2.7
  • Start Placebo, Then HCQ (Group A) vs Start Placebo, Then HCQ (Group C) · t-test, 2 sided · p = 0.576 · Mean difference (net): 0.5 · 95% CI -0.9 to 2
  • Stop HCQ, Then no Medication (Group E) vs Stop Placebo, Then no Medication (Group F) · t-test, 2 sided · p = 0.884 · Mean difference (net): -0.1 · 95% CI -1.9 to 1.7
  • Stop HCQ, Then no Medication (Group E) vs Stop HCQ, Then no Medication (Group G) · t-test, 2 sided · p = 0.563 · Mean difference (net): 0.8 · 95% CI -2.4 to 0.9

Adverse events

Collected over Adverse events were collected separately according their occurance during Start periods (8 weeks) or Stop periods (6 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Start Placebo, Then HCQ0/13 (0%)1/13 (7.7%)12/13 (92.3%)
Start HCQ, Then HCQ0/7 (0%)0/7 (0%)7/7 (100%)
Stop HCQ, Then no Medication0/4 (0%)0/4 (0%)4/4 (100%)
Stop Placebo, Then no Medication0/5 (0%)0/5 (0%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventStart Placebo, Then HCQStart HCQ, Then HCQStop HCQ, Then no MedicationStop Placebo, Then no Medication
Placebogroup Startarm SAE due to infectionInfections and infestations1/130/70/40/5
Most frequent other events
Most frequent other events
EventStart Placebo, Then HCQStart HCQ, Then HCQStop HCQ, Then no MedicationStop Placebo, Then no Medication
InfectionsInfections and infestations9/133/72/44/5
AEs gastrointestinal disorderInfections and infestations2/132/72/41/5
AE respiratory disorderRespiratory, thoracic and mediastinal disorders2/131/72/41/5
AE General disordersGeneral disorders1/131/70/41/5
AE Musculoskeletal and connective tissueMusculoskeletal and connective tissue disorders1/130/70/41/5
AE BloodBlood and lymphatic system disorders1/130/70/40/5
AE psychiatric disordersPsychiatric disorders1/130/70/40/5
AE Nervouse SystemNervous system disorders1/130/70/40/5
AE Eye disordersEye disorders1/130/70/40/5

Baseline characteristics

Age, Customized
Age, Customized(n amount of patients)Start Placebo (Group A), Then Continue HCQ (Group C)Start HCQ (Group B), Then Continue HCQ (Group D)Stop HCQ (Group E), Then Continued no Medication (Group G)Stop Placebo (Group F), Then Continued no Medication (Group H)Total
Number97.88.29.20
Sex: Female, Male
Sex: Female, Male(Participants)Start Placebo (Group A), Then Continue HCQ (Group C)Start HCQ (Group B), Then Continue HCQ (Group D)Stop HCQ (Group E), Then Continued no Medication (Group G)Stop Placebo (Group F), Then Continued no Medication (Group H)Total
Female1072322
Male722213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Start Placebo (Group A), Then Continue HCQ (Group C)Start HCQ (Group B), Then Continue HCQ (Group D)Stop HCQ (Group E), Then Continued no Medication (Group G)Stop Placebo (Group F), Then Continued no Medication (Group H)Total
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1694534
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Start Placebo (Group A), Then Continue HCQ (Group C)Start HCQ (Group B), Then Continue HCQ (Group D)Stop HCQ (Group E), Then Continued no Medication (Group G)Stop Placebo (Group F), Then Continued no Medication (Group H)Total
Germany1794535
O2 sat [%]
O2 sat [%](% 02 saturation)Start Placebo (Group A), Then Continue HCQ (Group C)Start HCQ (Group B), Then Continue HCQ (Group D)Stop HCQ (Group E), Then Continued no Medication (Group G)Stop Placebo (Group F), Then Continued no Medication (Group H)Total
Number92.693.993.794.80
08

Study locations

9 sites
  • Universitätsklinik für Kinder- und Jugendmedizin Tübingen
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Klinikum der Universität München, Haunersches Kinderspital
    München, Bavaria 80337, Germany
  • Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose
    Frankfurt am Main, Hesse 60590, Germany
  • Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie
    Giessen, Hesse 35385, Germany
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • St. Joseph- und St. Elisabeth Hospital gGmbH
    Bochum, North Rhine-Westphalia 44791, Germany
  • Uniklinikum Essen, Pädiatrische Pneumologie
    Essen, North Rhine-Westphalia 45122, Germany
  • Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig
    Leipzig, Saxony 04103, Germany
  • Charité Berlin, Klinik für Pädiatrie
    Berlin, 13353, Germany
09

References and documents

Publications

  • Griese M, Kohler M, Witt S, Sebah D, Kappler M, Wetzke M, Schwerk N, Emiralioglu N, Kiper N, Kronfeld K, Ruckes C, Rock H, Anthony G, Seidl E. Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. Trials. 2020 Apr 3;21(1):307. doi: 10.1186/s13063-020-4188-4. PubMed 32245508 ↗
  • Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol. 2015 Apr;50(4):410-9. doi: 10.1002/ppul.23133. Epub 2014 Dec 9. PubMed 25491573 ↗
  • Griese M, Kappler M, Stehling F, Schulze J, Baden W, Koerner-Rettberg C, Carlens J, Prenzel F, Nahrlich L, Thalmeier A, Sebah D, Kronfeld K, Rock H, Ruckes C; HCQ-study group; Wetzke M, Seidl E, Schwerk N. Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease. Orphanet J Rare Dis. 2022 Jul 23;17(1):289. doi: 10.1186/s13023-022-02399-2. PubMed 35871071 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Jun 2019, 46 months.

Results were first posted in Dec 2025, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2015
First posted
Nov 26, 2015
StartActual
Aug 21, 2015
Primary completionActual
Jun 27, 2019
CompletionActual
Sep 9, 2020
Results first posted
Dec 3, 2025
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02615938
Lead sponsor
Matthias Griese
Responsible party
Matthias Griese (Prof. Dr. med., Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Nov 26, 2015
Start date
Aug 21, 2015
Primary completion
Jun 27, 2019
Completion
Sep 9, 2020
Results posted
Dec 3, 2025
Last update
Dec 3, 2025

Study contacts

Matthias Griese
principal investigator · Hauner Children´s Hospital, LMU

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxychloroquine

Start the discussion